Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin in Acute on Chronic Liver Failure (ASIA Trial)
NCT03754400Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) in acute-on-chronic liver failure (ACLF), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Transplant-Free Survival at 28 days. Status: unknown.
02
Drugs
albumin (human)
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03754400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754400.